Successful use of recombinant factor VIIa for massive bleeding after caesarean section due to HELLP syndrome.
Zupancić Salek
S
S
Haemophilia Centre, Department of Haematology, Rebro University Hospital, Zagreb, Croatia. zvonko-salek@zg.tel.hr
Sokolić
V
V
Visković
T
T
Sanjug
J
J
Simić
M
M
Kastelan
M
M
D000328:Adult; D001803:Blood Transfusion; D002585:Cesarean Section / Q000009:adverse effects*; D004211:Disseminated Intravascular Coagulation / Q000209:etiology / Q000628:therapy*; D015942:Factor VIIa / Q000008:administration & dosage*; D005260:Female; D017359:HELLP Syndrome / Q000601:surgery*; D006801:Humans; D019106:Postoperative Hemorrhage / Q000628:therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000601:surgery*; D011994:Recombinant Proteins / Q000008:administration & dosage; D014592:Uterine Hemorrhage / Q000209:etiology / Q000628:therapy*
D011994:Recombinant Proteins; D015942:Factor VIIa